Cigarette smoking increases plasma levels of IL-6 and TNF-α

Shireen A. Al-tameemi1, Najwa J. Hameed1,2, Karina B. Gomes3 and Hussein A. Abid4,5

1Department of Chemistry, College of Science, University of Diyala, Baqubah 32001, Iraq
2Institute of Infection Immunity and Inflammation, College of Medical Veterinary and Life Sciences, University of Glasgow, Scotland, UK
3Department of Clinical and Toxicological Analyses, School of Pharmacy, Federal University of Minas Gerais, Minas Gerais, Brazil
4Scientific Affairs and Cultural Relations Section, Al-Nahrain University, Jadiriyah 10070, Iraq
5Department of Medical Laboratory Technology, Technical Institute of Baquba, Middle Technical University, Baqubah 32001, Iraq

ABSTRACT

Background and objective: Cigarette smoking is a leading cause of a wide range of critical health problems such as cancers, especially those related to the respiratory system. Although studies are continuing on the smoking-related inflammatory responses, limited reports are there to explore how such responses can be affected by the smoking intensity. Therefore, the current communication aimed to shed light on how smoking and smoking intensity can affect some inflammatory and anti-inflammatory biomarkers.

Methods: A total of 159 subjects (108 smokers and 51 non-smokers) were enrolled in this cross-sectional study. Their sociodemographic, smoking intensity and blood samples were obtained and processed using approved methodologies. The blood plasma samples were used to quantify interleukin 6 (IL-6), IL-10, tumor necrosis factor-alpha (TNF-α), C-reactive protein, D-dimer, and ferritin by using ELISA. The gained data was then analyzed using GraphPad Prism software to assess the variations.

Results: Both IL-6 and TNF-α are elevated markedly \( (p<0.001) \) in smoker subjects when compared with non-smoker ones (IL-6: \( 2.58 \pm 0.98 \) vs. \( 1.858 \pm 0.6256 \) pg/ml, TNF-α: \( 28.38 \pm 7.162 \) vs. \( 22.64 \pm 7.257 \) pg/ml). However, no significant differences were observed in other biomarkers comparing the groups, as well as no significant association was evidenced based on smoking intensity among smokers.

Conclusions: The findings might point to a relationship between smoking and the elevation of IL-6 and TNF-α levels in a cigarette dose-dependent manner.

Keywords biomarkers, cytokines, inflammation, smoking

INTRODUCTION

Smoking is a leading cause of lung function decline and chronic obstructive pulmonary disease (COPD) development, and its relationship with inflammation is well established.1
In spite of controversial reports, inflammatory cells, oxidative stress, and inflammatory mediators are the major contributors to smoking-related inflammation in humans.\(^1\) The reported change in inflammatory cells included an increase in neutrophils in chronic and acute exposure to cigarette smoking in both peripheral blood and bronchoalveolar lavage fluid.\(^1\)–\(^5\) Accumulated evidence has also shown that the acute exposure to cigarette smoking can result in immediate increase in oxidative stress and reactive species.\(^1\),\(^6\)–\(^8\) Moreover, mediators of inflammation in humans as well as animal and in vitro models such as plasma neutrophil elastase and leukotrienes B\(_4\), D\(_4\), E\(_4\) \(^4\)–\(^9\),\(^10\) and inflammatory cytokines (such as TNF-\(\alpha\))\(^11\) in acute smoking have also shown to be changed. However, limited reports are available on the relationship between the intensity of smoking and inflammatory responses.

This brief communication aimed to investigate the plasma levels of interleukin 6 (IL-6) and 10 (IL-10), tumor necrosis factor alpha (TNF-\(\alpha\)), high sensitivity C-reactive protein (hsCRP), D-dimer, and ferritin in apparently healthy smoker subjects and how they can be affected by the smoking intensity.

**MATERIALS AND METHODS**

**Study design and subjects**

This communication is a part of cross-sectional study conducted at the Technical Institute of Baquba (Baqubah, Iraq) between February and April 2021. The study included 108 smoker subjects (active smoking) and 51 non-smoker healthy individuals. All the included subjects were males (students or staff at the institute).

Smokers with no history of cardiovascular diseases, any other chronic or acute diseases, as well as those who received no vitamin supplements or chemical treatment during the previous 6 months were included in this study. But, those who suffer from any chronic or acute disorders, or those who received medical treatment or vitamin supplements were excluded.

The variables recorded were age, height, weight, smoking intensity (average of cigarettes smoked/day), occupation, educational level as well as medical history. The participants were subdivided according to current smoking status (smokers and non-smokers), educational level (School, University) and occupation (employee, non-employee). The Fagerstrom Test for Nicotine Dependence (FND) was modified and used to assess the smoking intensity.\(^12\),\(^13\) The smokers were divided accordingly into three groups: 1-20 cigarettes/ day group (n=18), 21-40 cigarettes/ day group (n=69), and >40 cigarettes/ day group (n=21).

**Blood sampling and analysis**

For each participant who was eligible to be enrolled, 5 milliliters (mL) of whole venous blood were drawn and collected on K\(_2\).EDTA tube and serum separator gel tube. The centrifugation was used, to separate blood samples, at 500 rpm for 15 minutes. The serum and
plasma thus obtained and then moved to another test tube to be preserved at freezer until the day of chemical analysis.

The biomarkers assessed were IL-6, IL-10, TNF-α, hsCRP, D-dimer and ferritin. All the biomarkers were evaluated in plasma samples using enzyme-linked immunosorbent assay (ELISA) kits from Abcam (USA) and the manufacturer’s instructions were followed. About 5% of the samples were tested twice to ensure the quality and performance of the kits.

**Statistical analysis**

The data was statistically evaluated by using GraphPad Prism 8.0. Categorical data was presented in frequencies and percentages, and numerical data was presented using mean±SD (or median and interquartile range, IQR, as appropriate). Independent sample t-test (or Mann-Whitney’s U test) for two-group comparisons or One-way ANOVA (or Kruskal-Wallis test) for three and more group comparisons were used to assess the differences in means or median. In addition, Chi-square test was used to explore the difference between nominal variables. The $p$-value of ≤0.05 was considered statistically significant.

**RESULTS AND DISCUSSION**

**General characteristics of study participants**

The sociodemographic characteristics of participants were listed in Table 1. No significant differences were noticed between smokers and non-smokers in regards to age, BMI, educational level, and occupation status.

| Variable                      | Smokers (n=108) | Non-smokers (n=51) | Significance |
|-------------------------------|-----------------|--------------------|-------------|
| Age (years)$^\dagger$         | 22.5(20,26)     | 22.0(20,26)        | NS          |
| BMI (Kg/m$^2$)                | 25.39±3.24      | 25.62±3.24         | NS          |
| Educational level – n(%)      |                 |                    |             |
| Secondary school              | 78(72.2)        | 37(72.55)          | NS          |
| Undergraduate school          | 30(27.8)        | 14(27.45)          |             |
| Occupation – n(%)             |                 |                    |             |
| Employee                      | 30(27.8)        | 14(27.28)          | NS          |
| Nonemployee                   | 78(72.2)        | 37(72.55)          |             |

NS, non-significant ($p$ value >0.05); $^\dagger$ (median, IQR)

**Biomarkers based on smoking status**

Inflammatory responses and cellular releases are essential contributors to lung injury and pathogenesis. Inflammatory biomarkers, both anti- and proinflammatory, were
reported to be disturbed in cigarette smoking. However, open literature search shows controversial results. To explore the effect of smoking on the studied biomarkers, they were investigated in the plasma of all smoker and non-smoker subjects and analyzed using unpaired t-test.

The results showed that both IL-6 and TNF-α are dramatically elevated in smoker persons when compared to non-smokers (IL-6 in pg/mL: 2.58±0.98 vs. 1.85±0.62, \( p < 0.001 \) and TNF-α in pg/mL: 28.38±7.16 vs. 22.64±7.25, \( p < 0.001 \)). Non-significant differences were noted in other biomarkers between smokers and non-smokers (IL-10 in pg/mL: 6.80±0.75 vs. 6.82±0.80, \( p = 0.884 \); hsCRP in mg/dL: 0.41±0.10 vs. 0.38±0.11, \( p = 0.255 \); D-dimer in mg/L: 0.20±0.04 vs. 0.20±0.06, \( p = 0.934 \); and ferritin in μg/L: 69.51±20.62 vs. 63.42±21.13, \( p = 0.09 \)) (Figure 1).

The current results regarding IL-6 and TNF-α levels are in conformity with wide-range studies conducted previously such as that of Helmersson et al. (2005) concerning IL-6, which was increased in current smokers compared with non-smokers, and that of Petrescu et al. (2010) in regards TNF-α. Petrescu et al found that TNF-α elevation is associated with smoking cigarettes in a dose-dependent manner. These two biomarkers are secreted by inflammatory cells in response to stimuli for the induction of inflammation. It is also well established that cigarette smoking activates oxidative stress and immune response, and this may explain why these biomarkers are elevated. For other biomarkers that are not significantly varied, as in previous authors' findings, our results may be limited with the sample size, race, gender, age, etc. of the study population. Accumulated evidence shows that race, gender and age have a significant influence on the inflammation, IL-10, hsCRP levels, D-dimer and ferritin levels.

![Figure 1](https://doi.org/10.47419/bjbabs.v3i01.108)

Figure 1  Plasma levels of inflammatory and hemostatic biomarkers in smokers and non-smoker participants. A) IL-6, B) IL-10, C) TNF-α, D) hsCRP, E) D-dimer, F) Ferritin. ** denote statistically significant change (\( p < 0.001 \))
Biomarkers based on smoking intensity

To assess the effects of smoking intensity on inflammatory and hemostatic biomarkers, the smokers were classified into three subgroups as detailed in methods section and their biomarkers’ results together with those of non-smoker subjects were analyzed by using one-way ANOVA test (or Kruskal Wallis test). The results showed that IL-6 level, in pg/mL, in non-smokers is the lowest (1.87±0.62) and increased in smokers as the number of cigarettes smoked increased (1-20/day: 2.26±1.28, 21-40/day: 2.62±0.93, and >40/day: 2.72±0.84). When compared statistically, the significant increase is only seen in smokers with higher number of smoked cigarettes per day (21-40, p<0.001 and >40, p=0.001). The TNF-α was also in its lowest level in non-smoker subjects (22.64±7.25 pg/mL) when compared to smokers with low smoking intensity (30.02±7.22 pg/mL), moderate intensity (28.24±6.68 pg/mL), and intensive smoking (26.99±8.78 pg/mL). No significant differences were found between the smokers’ biomarkers and those of non-smokers (Figure 2).

These results are in line with those of Aldaham et al (2015)26 and Petrescu et al (2010)17 who found that IL-6 and TNF-α are increased in a dose-dependent fashion. The elevation in IL-6 and TNF-α level together with smoking intensity, in the current study, may indicate their significant role as a mediator of inflammation in cigarette smoking.

In contrast with previous studies by Dwivedi et al. (2014)27 for IL-10, by Ohsawa et al. (2005)20 and Helmersson et al. (2005)16 for hsCRP, and by Wannamethee21 for D-dimer; our findings did not show significant differences in anti-inflammatory cytokine (IL-10) and inflammatory and hemostatic biomarkers. This may be affected by different small sample sizes.
sizes of various studies. Besides, other racial and anthropometric variations may contribute to such inconsistencies.

Nonetheless, the inherent limitations of cross-sectional studies are well-known and thus no conclusions about causality can be drawn from the current results. In particular, the small number of participants and especially in subgroups of smoking intensity and voluntary participation in the study may be the major limitations, as well as other sociodemographic variations in regards to environment, lifestyle and genetics.

**CONCLUSIONS**

Cigarette smoking is a leading cause of serious illness and cancers and its relation to inflammation is well established. This study investigated the influence of smoking and smoking intensity on the immune response in apparently healthy smoker males by measuring plasma levels of IL-6, IL-10, TNF-α, hsCRP, D-dimer, and ferritin. The results indicated significant rise in IL-6 and TNF-α of smoker persons’ plasma when compared with non-smokers. No significant difference in the studied biomarkers, based on smoking intensity, were found among smokers. It can be speculated that both IL-6 and TNF-α, as mediators of inflammation, might be useful biomarkers in the evaluation of smoking intensity-related lung inflammation.

**ACKNOWLEDGEMENTS**

The authors would like to thank the deanship, staff and students of the Technical Institute of Baqubah for their positive role and kind assistance during the practical part of the study.

**DECLARATIONS**

**Authors’ contributions**

Conceptualization, data curation, resources: SAA. Formal analysis, investigation, methodology, project administration, software, validation: SAA and HAA. Funding acquisition: N/A. Supervision: NJH. Writing-original draft: SAA and HAA. Writing-review & editing: HAA, NJH and KBG.

**Ethical approval and consent to participate**

The Deanship of Technical Institute of Baqubah approved this study (No.: #1181, Date: 01-03-2021) as well as the Department of Chemistry, College of Science, University of Diyala (No.: #447, Date: 04-02-2021). Written informed consent was obtained from each participant before participation.

**Conflict of interest**

The authors declare no conflict of interest.
Funding resources

No external fund was received.

REFERENCES

1. Van Der Vaart H, Postma DS, Timens W, Hacken NHT. Acute effects of cigarette smoke on inflammation and oxidative stress: a review. Thorax. 2004;59(8):713–721. Available from: 10.1136/thx.2003.012468.

2. Kuschner WG, Alessandro D, Wong A, Blanc H, D P. Dose-dependent cigarette smoking-related inflammatory responses in healthy adults. Eur Respir J. 1996;9(10):1989–1994. Available from: 10.1183/09031936.96.09101989.

3. Morrison D, Rahman I, Lannan S, Macnee W. Epithelial permeability, inflammation, and oxidant stress in the air spaces of smokers. Am J Respir Crit Care Med. 1999;159(2):473–479. Available from: 10.1164/ajrccm.159.2.9804080.

4. Janoff A, Raju L, Dearing R. Levels of elastase activity in bronchoalveolar lavage fluids of healthy smokers and nonsmokers. Am Rev Respir Dis. 1983;127(5):540–544. Available from: 10.1164/arrd.1983.127.5.540.

5. Hockertz S, Emmendörffer A, Scherer G. Acute effects of smoking and high experimental exposure to environmental tobacco smoke (ETS) on the immune system. Cell Biol Toxicol. 1994;10(3):177–190. Available from: 10.1007/BF00757561.

6. Montuschi P, Collins JV, Ciabattoni G, et al. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J Respir Crit Care Med. 2000;162(3):1175–1177. Available from: 10.1164/ajrccm.162.3.2001063.

7. Guatura SB, Martinez JA, Bueno S, Santos PC, L M. Increased exhalation of hydrogen peroxide in healthy subjects following cigarette consumption. Sao Paulo Med J. 2000;118(4):93–98. Available from: 10.1590/s1516-31802000000400004.

8. Balint B, Donnelly LE, Hanazawa T, Kharitonov SA, Barnes PJ. Increased nitric oxide metabolites in exhaled breath condensate after exposure to tobacco smoke. Thorax. 2001;56(6):456–461. Available from: 10.1136/thorax.56.6.456.

9. Abboud RT, Fera T, Johal S, Richter A, Gibson N. Effect of smoking on plasma neutrophil elastase levels. J Lab Clin Med. 1986;108(04):286–293. Available from: 10.5555/uri:pii:0022214386901678.

10. Drost EM, Selby C, Bridgeman M, Macnee W. Decreased leukocyte deformability after acute cigarette smoking in humans. Am Rev Respir Dis. 1993;148(5):1277–1283. Available from: 10.1164/ajrccm.148.5.1277.

11. Churg A, Wang RD, Tai H. Macrophage metalloelastase mediates acute cigarette smoke-induced inflammation via tumor necrosis factor-alpha release. Am J Respir Crit Care Med. 2003;167(8):1083–1089. Available from: 10.1164/rcmm.200212-1396OC.

12. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J
Inflammatory and hemostatic biomarkers in cigarette smoking

Shireen A., Al-tameemi; et al.

Addict. 1991;86(9):1119–1127. Available from: 10.1111/j.1360-0443.1991.tb01879.x.

13. Pomerleau CS, Majchrzak MJ, Pomerleau OF. Nicotine dependence and the Fagerström Tolerance Questionnaire: a brief review. J Subst Abuse. 1989;1(4):471–477. Available from: 10.1016/s0899-3289(20)30011-0.

14. Yang SR, Chida AS, Bauter MR, Shafiq N, Seweryniak K, Maggirwar SB, et al. Cigarette smoke induces proinflammatory cytokine release by activation of NF-kappaB and posttranslational modifications of histone deacetylase in macrophages. Am J Physiol Lung Cell Mol Physiol. 2006;291(1):46–57. Available from: 10.1152/ajplung.00241.2005.

15. Daloe MH, Avan A, Mirhafez SR, et al. Impact of cigarette smoking on serum pro- and anti-inflammatory cytokines and growth factors. Am J Mens Health. 2017;11(4):1169–1173. Available from: 10.1177/1557988315601724.

16. Helmersson J, Larsson A, Vessby B, Basu S. Active smoking and a history of smoking are associated with enhanced prostaglandin F(2alpha), interleukin-6 and F2-isoprostane formation in elderly men. Atherosclerosis. 2005;181(1):201–207. Available from: 10.1016/j.atherosclerosis.2004.11.026.

17. Petrescu F, Voican SC, Silosi I. Tumor necrosis factor-alpha serum levels in healthy smokers and nonsmokers. Int J Chron Obstruct Pulmon Dis. 2010;5:217–222. Available from: 10.2147/copd.s8330.

18. Visentin GP, Liu CY. Drug-Induced Thrombocytopenia. Hematol Oncol Clin North Am. 2007;21(4):685–696. Available from: 10.1016/j.hoc.2007.06.005.

19. Higaki M, Wada H, Mikura S. Interleukin-10 modulates pulmonary neutrophilic inflammation induced by cigarette smoke exposure. Exp Lung Res. 2015;Available from: 10.3109/01902148.2015.1096315.

20. Ohsawa M, Okayama A, Nakamura M. CRP levels are elevated in smokers but unrelated to the number of cigarettes and are decreased by long-term smoking cessation in male smokers. Prev Med (Baltim). 2005;41(2):651–656. Available from: 10.1016/j.ypmed.2005.02.002.

21. Wannamethee SG, Lowe G, Shaper AG, Rumley A, Lennon L, Whincup PH. Associations between cigarette smoking, pipe/cigar smoking, and smoking cessation, and haemostatic and inflammatory markers for cardiovascular disease. Eur Heart J. 2005;26(17):1765–1773. Available from: 10.1093/eurheartj/ehi183.

22. Albert MA, Ridker PM. Inflammatory biomarkers in African Americans: a potential link to accelerated atherosclerosis. Rev Cardiovasc Med. 2004;5(3):22–29.

23. Pieper CF, Rao KM, Currie MS, Harris TB, Cohen HJ. Age, functional status, and racial differences in plasma D-dimer levels in community-dwelling elderly persons. J Gerontol A Biol Sci Med Sci. 2000;55(11):649–57. Available from: 10.1093/gerona/55.11.m649.

24. Zacharski LR, Ornstein DL, Woloshin S, Schwartz LM. Association of age, sex, and race with body iron stores in adults: analysis of NHANES III data. Am Heart J. 2000;140(1):98–104. Available from: 10.1067/mhj.2000.106646.
25. Conway SE, M RO, Reilly M, Friedler B, Staff I, Fortunato G, et al. Sex differences and the role of IL-10 in ischemic stroke recovery. Biol Sex Differ. 2015;6(1):17–17. Available from: 10.1186/s13293-015-0035-9.

26. Aldaham S, Foote JA, Chow HH, Hakim IA. Smoking status effect on inflammatory markers in a randomized trial of current and former heavy smokers. Int J Inflam. 2015;p. 439396–439396. Available from: 10.1155/2015/439396.

27. Dwivedi S, Goel A, Khattri S, Mandhani A, Sharma P, Pant KK. Tobacco exposure by various modes may alter proinflammatory (IL-12) and anti-inflammatory (IL-10) levels and affects the survival of prostate carcinoma patients: an explorative study in North Indian population. Biomed Res Int. 2014;140(1):98–104. Available from: 10.1067/mhj.2000.106646.

AUTHOR BIOGRAPHY

Shireen A. Al-tameemi is a final-year student at the Department of Chemistry, College of Science, University of Diyala. She is interested in clinical chemistry topics related to oxidative stress, lipid metabolism, and fatty liver disease as well as clinical nutrition.

Najwa J. Hameed is a researcher and faculty member at the University of Diyala (Iraq). She got her Ph.D. in 2018 from the University of Glasgow (United Kingdom). Her main research interests in medical biochemistry include cytokines, inflammation and autoimmune diseases.

Karina B. Gomes Pharmacist, Ph.D. in Pharmaceutical Sciences. Associated professor at Federal University of Minas Gerais, Brazil. Research fields: polycystic ovary syndrome, diabetes mellitus, dementia and infertility with more than 200 papers and book chapters published.

Hussein A. Abid is a researcher at Al-Nahrain University (Scientific Affairs and Cultural Relations Section). His research interests include inflammatory responses, oxidative stress, diabetes mellitus, biomarkers, and therapeutic alternatives. He was ranked among the Top 10 International Reviewers for WoS-indexed journals in 2020, and also serves as an Editorial Board Member in some international journals of well-recognized publishers such as Elsevier and Wolters Kluwer.